Denali Therapeutics
Quarterly Financials
| Values in thousands | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|
Revenue | $0 | $0 | $0 | $0 |
Gross Profit | -3,045 | |||
EBITDA | -121,074 | -142,368 | -127,227 | -120,918 |
EBIT | -124,119 | -145,580 | -129,846 | -123,187 |
Net Income | -124,119 | -132,970 | -114,753 | -107,192 |
Net Change In Cash | 0 | 0 | 0 | 0 |
Free Cash Flow | -79,576 | -136,546 | -88,807 | -63,023 |
Cash | 141,207 | 56,947 | 174,960 | 90,636 |
Basic Shares | 171,449 | 171,222 | 170,086 | 169,456 |
Annual Financials
| Values in thousands | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
Revenue | $0 | $330,531 | $108,463 | $48,661 |
Gross Profit | 313,805 | 101,431 | 48,661 | |
EBITDA | -414,910 | -179,973 | -330,361 | -287,158 |
EBIT | -422,705 | -196,699 | -337,393 | -295,751 |
Net Income | -422,773 | -145,224 | -325,991 | -290,581 |
Net Change In Cash | 0 | 330,531 | 108,463 | 48,661 |
Cost of Revenue | -213,667 | |||
Free Cash Flow | -363,606 | -370,930 | -262,549 | -219,889 |
Cash | 174,960 | 127,106 | 218,044 | 293,477 |
Basic Shares | 164,473 | 137,370 | 125,530 | 121,524 |
Earnings Calls
| Quarter | EPS |
|---|---|
2025-09-30 | $0 |
2025-06-30 | -$0.72 |
2025-03-31 | -$0.78 |
2024-12-31 | -$0.67 |
